Compare The Coca-Cola Co K (KO) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs Natera Inc. Common Stock — how do they compare? The Coca-Cola Co K trades at $92.63 (market cap $387.70B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: The Coca-Cola Co K is far larger — about 6.8× Natera Inc. Common Stock's market cap, and The Coca-Cola Co K pays a 2.35% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold The Coca-Cola Co K for 154 Days and Natera Inc. Common Stock for 0 Days on average.
| KO | NTRA | |
|---|---|---|
Market Cap | $387.70B | $57.03B |
Volume | 15,313,783 | 1,131,157 |
Sector | Consumer Staples | Health |
52-Week High | $91.99 | $425.64 |
52-Week Low | $67.08 | $179.42 |
Typical Hold Time | 154 Days | 0 Days |
Enterprise Value | $414.87B | $56.18B |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $90.11, up 0.36% with strong technical momentum as it approaches resistance near $91. The company demonstrates robust fundamentals with Q2 2026 EPS of $0.97 beating expectations, maintaining a 61.89% gross margin and 28.56% net margin. Recent institutional buying activity and the upcoming $0.53 dividend payment reflect positive sentiment. The stock trades at a P/E of 27.06, above sector averages, while analyst consensus targets $95.75 with 60% buy ratings.
Outlook remains favorable with projected 2026 revenue growth to $50.1B and net income of $14.3B. Key risks include high valuation multiples and regional demand divergence. The technical setup suggests near-term consolidation with support at $88, while fundamental strength supports long-term dividend growth potential.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
